New drug interaction study aims to make camizestrant safer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy post-menopausal female participants with suitable veins for cannulation or repeated venipuncture. * Female participants must be post-menopausal as confirmed at the Screening Visit. Post-menopausal defined as amenorrhoea for at least 12 months or more without an alternative medical or surgical cause and confirmed by a follicle stimulating hormone (FSH) result of ≥ 30 Internation units/liter (IU/L). * Have a body mass index between 19 and 35 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive. * Must agree to not use warfarin or phenytoin (and other coumarin-derived vitamin K antagonist anticoagulants) during the study, and for 2 weeks after last administration of study intervention. Exclusion Criteria: * History of any clinically important disease or disorder. * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * History of any clinically significant cardiovascular, chronic respiratory disease, haematological, neurological or psychiatric disorder. * History of acute pulmonary insufficiency marked neuromuscular respiratory weakness, obsessional states, phobic states, sleep apnoea syndrome, and unstable myasthenia gravis. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * Any clinically important abnormalities in clinical chemistry, haematology, or urinalysis results. * Any relevant history or known risk factors of QT prolongation or have received drugs known to prolong QT interval. * Any positive result for serum Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV). * History of or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to camizestrant or the formulation excipients. * Presence of any contraindication to the probe substrate carbamazepine. * Presence of any contraindication to midazolam. * Have any active indication for therapeutic anticoagulation, and/or having taken an anticoagulant within 14 days of Screening Visit. * Part B only: Participants identified to carry human leukocyte antigen (HLA)-A\*3101 and/or HLA-B\*1502 allele. * Participants with bone marrow suppression or a history of bone marrow suppression or aplastic anaemia. * History of or ongoing clinically significant visual disturbances including but not limited to visual hallucinations, migraine with visual symptoms, blurred vision, frequent floaters/flashes associated with other symptoms such as dizziness. * Participants with family history of glaucoma or closed angle glaucoma or participants who are currently on anticholinergic medications. * Participants with an anticipated need for major surgery and/or any surgery requiring general anaesthesia during the participation in the study. * Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.